Table 3.

Cox's multivariate analysis for disease‐free and disease‐specific survival (n = 138)^a

	Number of patients	Disease‐free survival			Disease‐specific survival
		P‐valueb	HR	95% CI	P‐valueb	HR	95% CI
Age
≤70 years (ref)	63	0.026	1.80	1.07–3.01	0.002	3.98	1.65–9.59
>70 years	75
Preoperative treatment group
Short‐course RT	69	0.331	0.73	0.39–1.37	0.783	1.15	0.42–3.13
Long‐course (C)RT	31	0.431	1.31	0.67–2.59	0.040	3.19	1.05–9.66
No (C)RT (ref)	38
CIP2A MICI
≤Median (ref)	78	0.966	0.99	0.56–1.73	0.014	3.02	1.26–7.26
>Median	60
Disease recurrence
Yes	39				<0.0001	291.8	36.9–2307.1
No (ref)	99
Postoperative N
N1	35	0.180	1.49	0.83–2.65	0.831	1.11	0.43–2.83
N2	19	0.002	2.88	1.48–5.62	0.945	1.05	0.30–3.60
N0 (ref)	84
Sex
Female	62	0.200	0.70	0.40–1.21	0.473	0.75	0.35–1.63
Male (ref)	76
Lymphovascular invasion
Yes	43	0.071	1.63	0.96–2.77	0.666	1.19	0.54–2.62
No (ref)	95
CRM
≤2 mm	35	0.230	1.40	0.81–2.43	0.297	1.47	0.71–3.02
>2 mm (ref)	103

CI, confidence interval; CRM, circumferential resection margin; (C)RT, (chemo)radiotherapy; HR, hazard ratio; MICI, most intense cytoplasmic staining index; N, lymph node status; ref, reference.

^aComplete data for all the covariates were available for 138 patients.

^bCox regression test.

P‐values < 0.05 (in bold) are considered statistically significant.